白蛋白与不用白蛋白对脓毒性休克合并肾损伤患者肾脏替代治疗及死亡率的比较效果
这项回顾性多中心逆概率治疗加权队列研究纳入美国220家社区和教学医院的9,988例入院时脓毒性休克合并肾损伤成人患者,比较早期(入院24小时内)使用白蛋白与未使用白蛋白者的肾脏替代治疗或院内死亡复合结局。加权队列中,无白蛋白组复合结局发生率为33.8%,白蛋白组为39.7%(OR 1.29;95%CI 1.14-1.47;P<.001)。5%白蛋白未见显著差异(OR 1.07;95%CI 0.84-1.37),25%白蛋白风险显著增加(OR 1.43;95%CI 1.16-1.76)。提示早期白蛋白使用可能与复合结局增加相关,且主要与高胶体渗透压白蛋白相关。
要点
- 入院时脓毒性休克合并肾损伤患者,早期(入院24小时内)使用白蛋白者复合结局(RRT或院内死亡)发生率39.7%,未使用者为33.8%(OR 1.29;95%CI 1.14-1.47;P<.001)。
- 5%白蛋白与复合结局无显著差异(OR 1.07;95%CI 0.84-1.37)。
- 25%白蛋白与复合结局风险显著增加相关(OR 1.43;95%CI 1.16-1.76)。
- 作者认为,早期白蛋白使用可能与复合结局增加相关,且此风险主要与高胶体渗透压白蛋白而非等胶体渗透压白蛋白相关。
适用人群与场景
- 成人患者,入院时诊断为脓毒性休克并合并肾损伤。
- 来自美国220家地理分布多样的社区和教学医院。
研究设计与关键结果
- 研究类型:回顾性多中心逆概率治疗加权队列研究,纳入220家美国社区和教学医院。
- 样本量:最终队列9,988例,其中未使用白蛋白7,929例,使用白蛋白2,059例。
- 人群特征:平均年龄67.8±14.8岁,女性占46.3%,入院当日平均估算肾小球滤过率为32±12 mL/min/1.73 m2。
- 主要终点:加权队列中,肾脏替代治疗或院内死亡复合结局在未使用白蛋白组发生率为33.8%,使用白蛋白组为39.7%(OR 1.29;95%CI 1.14-1.47;P<.001)。
- 次要终点:5%白蛋白与复合结局无显著差异(OR 1.07;95%CI 0.84-1.37);25%白蛋白与复合结局风险显著增加相关(OR 1.43;95%CI 1.16-1.76)。
证据类型、等级与局限
- 证据类型:回顾性多中心逆概率治疗加权队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在入院时脓毒性休克合并肾损伤患者中,早期使用白蛋白可能与肾脏替代治疗或院内死亡复合结局增加相关;此风险主要与高胶体渗透压白蛋白而非等胶体渗透压白蛋白相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Albumin infusions may be renally protective or harmful in patients with septic shock who have kidney impairment. This can affect the need for renal replacement therapy (RRT) and in-hospital mortality.
RESEARCH QUESTION: Does the early use of albumin mitigate the need for RRT or in-hospital mortality in patients with septic shock and kidney impairment on hospital admission?
STUDY DESIGN AND METHODS: This was a retrospective multicenter inverse probability-of-treatment weighted cohort study conducted in 220 geographically diverse community and teaching hospitals across the United States. Adult patients were included if they had septic shock and kidney impairment on hospital admission. Patients were categorized as those who received albumin (within 24 hours of admission) or no albumin during hospitalization. Proportion of patients with RRT or in-hospital mortality were compared between groups.
RESULTS: Of the 9,988 patients included in the final cohort, 7,929 did not receive albumin and 2,059 received albumin. Patients had a mean ± SD age of 67.8 ± 14.8 years, 46.3% were female, and the mean estimated glomerular filtration rate was 32 ± 12 mL/min/1.73 m2 on the day of admission. In the weighted cohort, the composite outcome of RRT or in-hospital mortality occurred in 33.8% without albumin and 39.7% with albumin treatment (OR, 1.29; 95% CI, 1.14-1.47; P < .001). There was no significant difference with 5% albumin (OR, 1.07; 95% CI, 0.84-1.37), but there was a significantly increased risk with 25% albumin (OR, 1.43; 95% CI, 1.16-1.76).
INTERPRETATION: In patients with septic shock and kidney impairment on hospital admission, early albumin use may be associated with an increased composite outcome of RRT or in-hospital mortality. This increased risk is most associated with hyperoncotic albumin rather than iso-oncotic albumin.
参考来源
- Patanwala AE, Flannery AH, Mehta HB, et al. Comparative Effectiveness of Albumin vs No Albumin on Renal Replacement Therapy and Mortality in Patients With Septic Shock and Renal Impairment. Chest. 2024. PMID: 39426720. doi:10.1016/j.chest.2024.10.012
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。